{
  "drug_name": "Cefpirome",
  "tradename": "Cefrom",
  "usage_and_dosing": {
    "general": [
      "Cefpirome is a parenteral 4th generation cephalosporin with in vitro activity against aerobic Gram-positive cocci and most Enterobacteriaceae. It has activity against some P. aeruginosa and is inactive against anaerobic bacilli.",
      "Not available in the US."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV q12h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "2",
    "half_life_esrd": "14.5",
    "dose_renal_function_normal": "2 gm IV q12h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm q12h. CrCl <10: 1 gm q24h",
    "hemodialysis": "1 gm q24h (AD on dialysis days)",
    "capd": "0.5 gm 3x/wk",
    "crrt": "2 gm load, then 1 gm q12h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": {
      "ecmo": "Increased dosing suggested: 2 gm IV (bolus) q8h, or 2 gm IV (over 4 hr) q12h. See ECMO Drug Dosing Adjustment for details."
  },
  "adverse_effects": [
    "For class-wide adverse effects, see Cephalosporins, Overview.",
    "Cefpirome has the same R1 side chain as cefotaxime, cefpodoxime, cefditoren, ceftizoxime, ceftriaxone, and cefepime. Cross-allergenicity may occur."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "No data",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "full_comparative_spectrum_of_activity": true
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "80 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "10",
    "volume_of_distribution_vd_l_vss": "21 L (Vss)",
    "avg_serum_half_life_hr": "2",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "5-15",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "150 (1 gm IV, 0-inf)"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ]
}
